KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity: 2011-2020

Historic Debt to Equity for Nektar Therapeutics (NKTR) over the last 8 years, with Mar 2020 value amounting to $0.39.

  • Nektar Therapeutics' Debt to Equity rose 159.22% to $0.39 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.39, marking a year-over-year increase of 159.22%. This contributed to the annual value of $0.36 for FY2019, which is 148.88% up from last year.
  • Nektar Therapeutics' Debt to Equity amounted to $0.39 in Q1 2020, which was up 9.71% from $0.36 recorded in Q4 2019.
  • Nektar Therapeutics' Debt to Equity's 5-year high stood at $72.16 during Q2 2017, with a 5-year trough of -$880.47 in Q1 2016.
  • Moreover, its 3-year median value for Debt to Equity was $0.16 (2019), whereas its average is $0.65.
  • In the last 5 years, Nektar Therapeutics' Debt to Equity crashed by 54,551.96% in 2016 and then skyrocketed by 1,267.67% in 2017.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Debt to Equity stood at $2.76 in 2016, then climbed by 1.06% to $2.79 in 2017, then crashed by 94.85% to $0.14 in 2018, then skyrocketed by 148.88% to $0.36 in 2019, then skyrocketed by 159.22% to $0.39 in 2020.
  • Its last three reported values are $0.39 in Q1 2020, $0.36 for Q4 2019, and $0.17 during Q3 2019.